Asgard Therapeutics

✨ Exciting News! ✨ We are proud to share that Asgard Therapeutics has been selected as a finalist for the European Lifestars Awards - Celebrating Life Science Leaders 2024! 🎉 We are honored to be recognized in two categories: 🏆 Biotech Company of the Year and Women-Led Business Leader of the Year, with our CEO and co-founder, Cristiana Pires, leading the way. We look forward to the awards ceremony on November 18 in London and to celebrating alongside many inspiring leaders in the life sciences industry! #Biotech #WomenInLeadership #LifeSciences #AsgardTherapeutics

🚀 Meet Asgard Therapeutics at CICON 2024 and ESMO Congress 2024! We’re excited to share that Filipe Pereira, Co-founder and Head of Innovation, will be presenting at CICON 2024. His talk, titled “A cancer immunotherapy modality based on dendritic cell reprogramming in vivo,” will take place on September 9th at 5:15 PM during Proffered Session - What’s on the Horizon: New Tools, Technologies, and Approaches in Cancer Immunotherapy, Part II. Don't miss the chance to hear the latest news from our recent publication in the journal Science! 📅 CICON 2024: September 9-11th  📍 Washington D.C.  🎙 Filipe Pereira presenting on September 9th at 5:15 PM  🤝 Fabio Rosa, Head of Research, will also be attending. You can also connect with Xiaoli Huang, Project Director in Preclinical Pharmacology, at the ESMO Congress 2024 in Barcelona! 📅 ESMO Congress 2024: September 13-17th  📍 Barcelona Spain We look forward to seeing you! #CICON2024 #ESMO2024 #AsgardTherapeutics

Check out this great article in AACR’s Cancer Discovery News about our new paper published in Science regarding Asgard’s cell reprogramming approach to cancer.    The article, Reprogramming Turns Cancer Cells into Immune Allies, can be found here: https://bit.ly/3yYmxrJ   Cancer Discovery News wrote that converting “tumor cells into immune-boosting dendritic cells shows promise in mice, setting the stage for human trials.”   The article also quoted David Tran, MD, PhD, of the University of Southern California in Los Angeles, as saying: “This paper establishes that in situ reprogramming is possible… It paves the way for potential therapeutic applications.”

Asgard Therapeutics is making fantastic progress towards taking its first-in-class approach to cancer immunotherapy into the clinic.   Last night Asgard had a milestone paper published in the journal Science. The study, co-led by Asgard and the Pereira Lab, provides proof-of-concept data demonstrating that our platform transforms tumor cells into antigen-presenting dendritic cells in living beings and not just in vitro.   The reprogrammed cells elicit “systemic and long-term antitumor immunity”, found the authors, who concluded: “Our study paves the way for human clinical trials on in vivo immune cell reprogramming for cancer immunotherapy.”   Meanwhile, Asgard is gearing up for clinical development by establishing CMC processes for scale-up manufacturing of GMP-grade AT-108 for Phase I/II trials. Click the link in the comments below to read the press release and the paper.

Asgard Therapeutics has today had a landmark paper published in the prestigious journal Science, demonstrating in vivo proof-of-concept for its first-in-class approach to cancer immunotherapy.    Novel data published in the study, co-led by the Filipe Pereira Lab at Lund University, demonstrate that our lead product AT-108 reprograms tumor cells, directly within the immunosuppressed tumor microenvironment, into antigen-presenting dendritic cells. This causes strong, antigen-specific, anti-tumor responses to be mounted, resulting in durable tumor shrinkage even upon metastatic challenge.    The study paves the way for human clinical trials of AT-108 in vivo immune cell reprogramming for cancer immunotherapy.   The graphic depicts a tumor cell being ‘unlocked’ by AT-108 and consequently transformed into an antigen-presenting dendritic cell. The dendritic cell is depicted as shining as it illuminates the way for the immune system to target ‘cold and dark’ tumors - thus generating robust, long-lasting and systemic anti-tumor responses. Graphic by Joana C. Carvalho. Click the link in the comments below to read the press release and the paper.

Curious about Asgard Therapeutics' first-in-class immunotherapy? Our lead program, AT-108, directly reprograms tumor cells into functional dendritic cells, enabling cancer cells to kick-start immune responses against themselves. Learn more about our technology and current development stage in the Biopharma Dealmaker one-pager. Find the link in the comments. Keep an eye out for some exciting news coming later this week! 🚀 

📢 Exciting News!    Asgard Therapeutics, in collaboration with the Pereira lab, is happy to announce the publication of a preprint in bioRxiv called “A cancer immunotherapy modality based on dendritic cell reprogramming in vivo” showcasing in vivo proof-of-concept for our lead program AT-108, a replication-deficient adenoviral vector encoding our proprietary combination of dendritic cell-inducing transcription factors. The study supports the ability of AT-108 to: • Transduce and reprogram tumor cells to conventional type 1 dendritic cells in vivo.  • Remodel the tumor microenvironment and promote recruitment and expansion of polyclonal cytotoxic T cells. • Induce complete tumor regression in checkpoint blockade-resistant models. • Establish long-term systemic immunity.   This research represents a significant milestone for Asgard Therapeutics' lead program, AT-108, which is currently in the preclinical development stage and expected to reach IND-readiness by 2026.    We extend our gratitude to all co-authors for their great contributions to this groundbreaking research.    Read the full pre-print paper on bioRxiv: bit.ly/463KeKY

Don't miss out! Meet Asgard Therapeutics at #ISSCR2024 in Hamburg, Germany, from July 10-13, 2024! Join our co-founder and CEO Cristiana Pires as she speaks about in vivo direct reprogramming of tumor cells to dendritic cells as a new cancer immunotherapy modality. She will be speaking at the session: “Plenary VI: the clinical reality and promise of cell and gene therapies” on Saturday, July 13, 2024, from 10:45 AM – 11:05 AM CEST in Hall 1, Level 2. We’re excited to connect! #AsgardTherapeutics #ISSCR2024 #Immunooncology

Don't miss Asgard Therapeutics at #ISSCR2024 in Hamburg, Germany, from July 10-13, 2024!    Join our co-founder and CEO Cristiana Pires as she speaks about in vivo direct reprogramming of tumor cells to dendritic cells as a new cancer immunotherapy modality.    She will be speaking at the session: “Plenary VI: the clinical reality and promise of cell and gene therapies” on Saturday, July 13, 2024, from 10:45 AM – 11:05 AM CEST in Hall 1, Level 2.    We’re excited to connect with the global stem cell and regenerative medicine community!   #AsgardTherapeutics #ISSCR2024 #Immunooncology

🚀 Asgard Therapeutics is excited to share highlights from our successful 3rd Annual SAB meeting held in Lund. The SAB gathered to review key updates on our lead program, AT-108, designed to initiate efficient and personalized immune responses. Discussions centered on ongoing CMC and IND enabling studies, as well as strategic regulatory and clinical pathways, all crucial steps towards our goal of being IND-ready by mid 2026. Cristiana Pires, PhD, Co-Founder and CEO of Asgard Therapeutics, said: "We are thrilled to harness the translational expertise of our global SAB and benefit from the helpful feedback of Aurélien Marabelle, Ulrich Lauer, Joshua Brody, MD and Johanna Olweus, which have enabled us to refine our strategy and streamline our development process. Since our last meeting in September 2023, we achieved significant milestones, including closing a €30M Series A funding round. Their guidance will bring us closer to executing our Series A plans and advancing towards our first-in-human studies." #AsgardTherapeutics #AT108 #ImmunoOncology